Shattuck Labs
Expanding the Boundaries of Biologic Medicines
Expanding the Boundaries of Biologic Medicines
Shattuck Labs is a biotechnology startup founded in 2016 and based in the United States. The company is at the forefront of developing bi-functional fusion proteins for the treatment of cancer and autoimmune diseases. Its proprietary Agonist Redirected Checkpoint, ARC®, platform is designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules, offering a novel approach to biologic medicine.
Shattuck's lead program, SL-172154 (SIRPα-Fc-CD40L), is currently in a Phase 1 trial, targeting the CD47 immune checkpoint while agonizing the CD40 pathway. Another promising compound, SL-279252 (PD1-Fc-OX40L), is undergoing Phase 1 trials in collaboration with Takeda Pharmaceuticals. The company is also advancing the GADLEN™ platform, which aims to bridge gamma delta T cells to tumor antigens for cancer treatment.
The company's last investment of $50.00MPost-IPO Equity was made on 21 December 2023, marking a significant milestone in its growth and development. Shattuck Labs operates from offices in Austin, Texas and Durham, North Carolina.
As a clinical-stage biotechnology company with promising developments in novel biologic medicine, Shattuck Labs demonstrates a strong potential for disrupting the biopharma and biotechnology industries. With notable investments and strategic collaborations, the company is well-positioned to make a meaningful impact in the treatment of cancer and autoimmune diseases.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $50.00M | - | 21 Dec 2023 | |
| Series B | $118.00M | 8 |
|
15 Jun 2020 |
| Series A | $46.62M | - | 24 May 2018 | |
| Debt Financing | $7.00M | - | 10 Apr 2017 | |
| Debt Financing | $3.40M | - | 22 Aug 2016 |
No recent news or press coverage available for Shattuck Labs.
We care about your data, and we'd love to use cookies make your experience better.
